Characteristics of study population: adult patients with incident primary AIHA treated with rituximab
| Variables . | Total population . | Patients hospitalized with infection . | Patients not hospitalized with infection . |
|---|---|---|---|
| (n = 959) . | (n = 169) . | (n = 790) . | |
| Mean age, y (SD) | 67.5 (17.6) | 73.4 (16.5) | 66.3 (17.6) |
| Male sex, n (%) | 378 (39.4) | 70 (41.4) | 308 (39.0) |
| Mean Charlson Comorbidity Index score∗ (SD) | 1.5 (2.5) | 2.2 (2.8) | 1.3 (2.4) |
| Comorbidities, n (%) | |||
| Myocardial infarction | 76 (7.9) | 30 (17.8) | 46 (5.8) |
| Congestive heart failure | 123 (12.8) | 35 (20.7) | 88 (11.1) |
| Peripheral vascular disease | 87 (9.1) | 24 (14.2) | 63 (8.0) |
| Cerebrovascular disease | 81 (8.4) | 23 (13.6) | 58 (7.3) |
| Hemiplegia | 35 (3.6) | 14 (8.3) | 21 (2.7) |
| Dementia | 34 (3.5) | 11 (6.5) | 24 (2.9) |
| Chronic pulmonary disease | 84 (8.6) | 22 (13.0) | 62 (7.8) |
| Diabetes | 180 (18.8) | 46 (27.2) | 134 (17.0) |
| Diabetes with end-organ damage† | 71 (7.4) | 23 (13.6) | 48 (6.1) |
| Moderate or severe renal disease | 96 (10.0) | 24 (14.2) | 72 (9.1) |
| Mild liver disease | 47 (4.9) | 8 (4.7) | 39 (4.9) |
| Moderate or severe liver disease | 22 (2.3) | 6 (3.6) | 16 (2.0) |
| Ulcer disease | 23 (2.4) | 8 (4.7) | 15 (1.9) |
| Tumor | 143 (14.9) | 32 (18.9) | 111 (14.1) |
| Metastatic solid tumor | 21 (2.2) | 5 (3.0) | 16 (2.0) |
| Splenectomy, n (%) | 29 (3.0) | 5 (3.0) | 24 (2.9) |
| Mean red blood cell transfusions‡ (SD) | 0.9 (2.5) | 1.5 (3.9) | 0.8 (2.0) |
| All-cause hospitalization§ | |||
| Mean (SD) | 3.5 (3.6) | 4.8 (3.3) | 3.3 (3.7) |
| Mean cumulative duration, d (SD) | 6.1 (9.0) | 5.6 (8.0) | 6.2 (9.3) |
| All-cause deaths,§ n (%) | 87 (9.1) | 39 (23.1) | 48 (6.1) |
| Drug exposures, n (%) | |||
| Corticosteroids|| | 619 (64.5) | 112 (66.3) | 507 (64.2) |
| Other immunosuppressants|| | 43 (4.5) | 5 (3.0) | 38 (4.8) |
| Pneumococcal vaccination¶ | 230 (24.0) | 30 (17.8) | 200 (25.3) |
| Influenza vaccination¶ | 354 (36.9) | 73 (43.2) | 281 (35.6) |
| Variables . | Total population . | Patients hospitalized with infection . | Patients not hospitalized with infection . |
|---|---|---|---|
| (n = 959) . | (n = 169) . | (n = 790) . | |
| Mean age, y (SD) | 67.5 (17.6) | 73.4 (16.5) | 66.3 (17.6) |
| Male sex, n (%) | 378 (39.4) | 70 (41.4) | 308 (39.0) |
| Mean Charlson Comorbidity Index score∗ (SD) | 1.5 (2.5) | 2.2 (2.8) | 1.3 (2.4) |
| Comorbidities, n (%) | |||
| Myocardial infarction | 76 (7.9) | 30 (17.8) | 46 (5.8) |
| Congestive heart failure | 123 (12.8) | 35 (20.7) | 88 (11.1) |
| Peripheral vascular disease | 87 (9.1) | 24 (14.2) | 63 (8.0) |
| Cerebrovascular disease | 81 (8.4) | 23 (13.6) | 58 (7.3) |
| Hemiplegia | 35 (3.6) | 14 (8.3) | 21 (2.7) |
| Dementia | 34 (3.5) | 11 (6.5) | 24 (2.9) |
| Chronic pulmonary disease | 84 (8.6) | 22 (13.0) | 62 (7.8) |
| Diabetes | 180 (18.8) | 46 (27.2) | 134 (17.0) |
| Diabetes with end-organ damage† | 71 (7.4) | 23 (13.6) | 48 (6.1) |
| Moderate or severe renal disease | 96 (10.0) | 24 (14.2) | 72 (9.1) |
| Mild liver disease | 47 (4.9) | 8 (4.7) | 39 (4.9) |
| Moderate or severe liver disease | 22 (2.3) | 6 (3.6) | 16 (2.0) |
| Ulcer disease | 23 (2.4) | 8 (4.7) | 15 (1.9) |
| Tumor | 143 (14.9) | 32 (18.9) | 111 (14.1) |
| Metastatic solid tumor | 21 (2.2) | 5 (3.0) | 16 (2.0) |
| Splenectomy, n (%) | 29 (3.0) | 5 (3.0) | 24 (2.9) |
| Mean red blood cell transfusions‡ (SD) | 0.9 (2.5) | 1.5 (3.9) | 0.8 (2.0) |
| All-cause hospitalization§ | |||
| Mean (SD) | 3.5 (3.6) | 4.8 (3.3) | 3.3 (3.7) |
| Mean cumulative duration, d (SD) | 6.1 (9.0) | 5.6 (8.0) | 6.2 (9.3) |
| All-cause deaths,§ n (%) | 87 (9.1) | 39 (23.1) | 48 (6.1) |
| Drug exposures, n (%) | |||
| Corticosteroids|| | 619 (64.5) | 112 (66.3) | 507 (64.2) |
| Other immunosuppressants|| | 43 (4.5) | 5 (3.0) | 38 (4.8) |
| Pneumococcal vaccination¶ | 230 (24.0) | 30 (17.8) | 200 (25.3) |
| Influenza vaccination¶ | 354 (36.9) | 73 (43.2) | 281 (35.6) |
SD, standard deviation.
Adapted for the French national health database by Bannay et al.11
All patients in this “end-organ damage” subgroup were also included in the “diabetes” subgroup.
Number of transfusions between the diagnosis of AIHA and the index date (first infusion of rituximab).
During the 6-month rituximab exposure period after the index date (first infusion of rituximab).
Exposed at least once during the 6-month rituximab exposure period after the index date (first infusion of rituximab).
Before the index date (first infusion of rituximab).